Operating Lease, Liability of GT Biopharma, Inc. from 31 Mar 2022 to 31 Mar 2024

Taxonomy & unit: us-gaap: USD
Description: Present value of lessee's discounted obligation for lease payments from operating lease.
Summary: GT Biopharma, Inc. quarterly Operating Lease, Liability in USD history and change rate from 31 Mar 2022 to 31 Mar 2024.
GT Biopharma, Inc. Operating Lease, Liability for the quarter ending 31 Mar 2024 was $30,000, a 81% decline year-over-year.
Source SEC data: View on sec.gov

Operating Lease, Liability, Quarterly (USD)

Operating Lease, Liability, YoY Quarterly Change (%)

GT Biopharma, Inc. Quarterly Operating Lease, Liability (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2024	$30,000	-$127,000	-81%	31 Mar 2024	10-Q	15 May 2024	2024	Q1
Q4 2023	$58,000,000	+$57,826,000	+33233%	31 Dec 2023	10-K	26 Mar 2024	2023	FY
Q3 2023	$97,000	-$216,903,000		30 Sep 2023	10-Q	01 Nov 2023	2023	Q3
Q2 2023	$156,000	-$245,844,000		30 Jun 2023	10-Q	07 Aug 2023	2023	Q2
Q1 2023	$157,000	-$276,843,000		31 Mar 2023	10-Q	15 May 2023	2023	Q1
Q4 2022	$174,000			31 Dec 2022	10-K	30 Mar 2023	2022	FY
Q3 2022	$217,000,000^*			30 Sep 2022	10-Q	31 Oct 2022	2022	Q3
Q2 2022	$246,000,000^*			30 Jun 2022	10-Q	15 Aug 2022	2022	Q2
Q1 2022	$277,000,000^*			31 Mar 2022	10-Q	16 May 2022	2022	Q1

* An asterisk sign (*) next to the value indicates that the value is likely invalid.